IL23R

Summary

IL23R (interleukin 23 receptor, HGNC:19100) is a protein-coding gene on chromosome 1p31.3, encoding Interleukin-23 receptor (Q5VWK5). Associates with IL12RB1 to form the interleukin-23 receptor.

The protein encoded by this gene is a subunit of the receptor for IL23A/IL23. This protein pairs with the receptor molecule IL12RB1/IL12Rbeta1, and both are required for IL23A signaling. This protein associates constitutively with Janus kinase 2 (JAK2), and also binds to transcription activator STAT3 in a ligand-dependent manner.

Source: NCBI Gene 149233 — RefSeq curated summary.

At a glance

• Gene–disease (curated): inherited susceptibility to mycobacterial diseases (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 61
• Clinical variants (ClinVar): 445 total
• Phenotypes (HPO): 85
• Druggable target: yes
• MANE Select transcript: NM_144701

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19100
Approved symbol	IL23R
Name	interleukin 23 receptor
Location	1p31.3
Locus type	gene with protein product
Status	Approved
Aliases	IL-23R
Ensembl gene	ENSG00000162594
Ensembl biotype	protein_coding
OMIM	607562
Entrez	149233

Gene structure

Transcript identifiers

Ensembl transcripts: 33 — 25 nonsense_mediated_decay, 8 protein_coding

ENST00000347310, ENST00000425614, ENST00000473881, ENST00000637002, ENST00000697148, ENST00000697149, ENST00000697150, ENST00000697151, ENST00000697152, ENST00000697153, ENST00000697154, ENST00000697155, ENST00000697156, ENST00000697157, ENST00000697158, ENST00000697159, ENST00000697160, ENST00000697161, ENST00000697162, ENST00000697163, ENST00000697164, ENST00000697165, ENST00000697222, ENST00000697223, ENST00000697224, ENST00000697225, ENST00000697226, ENST00000697227, ENST00000697228, ENST00000697229, ENST00000697230, ENST00000697231, ENST00000697232

RefSeq mRNA: 1 — MANE Select: NM_144701 NM_144701

CCDS: CCDS637

Canonical transcript exons

ENST00000347310 — 11 exons

Exon	Start	End
ENSE00001789888	67200737	67200897
ENSE00001855149	67166454	67166541
ENSE00001954059	67258478	67259979
ENSE00003794779	67168092	67168190
ENSE00003795359	67169342	67169638
ENSE00003800467	67182836	67182959
ENSE00003969758	67236713	67236802
ENSE00003969762	67219574	67219730
ENSE00003969763	67240179	67240281
ENSE00003969765	67206910	67207055
ENSE00003969767	67255837	67255927

Expression profiles

Bgee: expression breadth broad, 39 present calls, max score 93.98.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3277 / max 25.8129, expressed in 117 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
3402	0.1714	61
3403	0.1563	56

Top tissues by expression

221 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	93.98	gold quality
oocyte	CL:0000023	92.83	gold quality
adrenal tissue	UBERON:0018303	72.27	gold quality
amniotic fluid	UBERON:0000173	71.00	gold quality
rectum	UBERON:0001052	60.31	gold quality
epithelium of nasopharynx	UBERON:0001951	55.24	gold quality
islet of Langerhans	UBERON:0000006	55.23	gold quality
buccal mucosa cell	CL:0002336	54.75	silver quality
vermiform appendix	UBERON:0001154	54.51	gold quality
colonic epithelium	UBERON:0000397	54.17	silver quality
adrenal gland	UBERON:0002369	53.04	gold quality
gall bladder	UBERON:0002110	52.50	gold quality
right adrenal gland	UBERON:0001233	51.98	gold quality
right adrenal gland cortex	UBERON:0035827	51.63	gold quality
caecum	UBERON:0001153	51.31	gold quality
left adrenal gland	UBERON:0001234	50.89	gold quality
sperm	CL:0000019	50.65	gold quality
mucosa of transverse colon	UBERON:0004991	50.10	gold quality
left adrenal gland cortex	UBERON:0035825	48.63	gold quality
adrenal cortex	UBERON:0001235	48.61	gold quality
lymph node	UBERON:0000029	47.53	silver quality
duodenum	UBERON:0002114	46.45	gold quality
tonsil	UBERON:0002372	45.30	gold quality
skin of hip	UBERON:0001554	44.67	silver quality
lower lobe of lung	UBERON:0008949	44.30	silver quality
oviduct epithelium	UBERON:0004804	44.13	silver quality
cardia of stomach	UBERON:0001162	44.03	gold quality
transverse colon	UBERON:0001157	43.60	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
bone marrow cell	CL:0002092	43.35	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-70580	yes	1558.45
E-CURD-122	yes	10.16
E-MTAB-6678	yes	6.91
E-ANND-3	no	4.18

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): RORC

miRNA regulators (miRDB)

47 targeting IL23R, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-3180-5P	99.82	69.12	2422
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-4708-3P	99.51	67.99	870
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-5571-5P	99.49	66.99	1764
HSA-MIR-147B-5P	99.45	70.62	2432
HSA-MIR-4735-5P	99.43	68.49	1780
HSA-MIR-297	99.40	69.58	1418
HSA-MIR-19A-5P	99.36	66.93	1675
HSA-MIR-19B-1-5P	99.36	67.07	1669
HSA-MIR-19B-2-5P	99.36	67.07	1669
HSA-MIR-580-5P	99.28	70.94	1776
HSA-MIR-3125	99.14	68.49	2269
HSA-MIR-4650-3P	99.01	68.39	1062
HSA-MIR-3916	98.99	68.04	2155
HSA-MIR-6859-5P	98.99	68.07	2049

Literature-anchored findings (GeneRIF, showing 40)

• the preferential expression of certain IL-23R spliced variants may be a contributive factor to the pathogenesis of certain cancers (PMID:16372191)
• findings show a highly significant association between Crohn’s disease and the IL23R gene on chromosome 1p31 (PMID:17068223)
• IL12B and IL23R genes play a fundamental role in psoriasis pathogenesis. (PMID:17236132)
• IL-23 receptor (IL-23R) gene protects against pediatric Crohn’s disease. (PMID:17309073)
• This study shows an association between IL23R and all subphenotypes of Crohn’s disease with a smaller effect on ulcerative colitis. (PMID:17484863)
• IL23R is a susceptibility gene for inflammatory bowel disease with suggestive epistasis with the IBD5 locus in the Crohn’s disease population (PMID:17508420)
• No evidence of positive association of IL23R with Crohn’s disease was found in the Japanese population. (PMID:17534574)
• Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. (PMID:17587057)
• The data reported provide direct evidence that some allelic variants or haplogroups of IL-23R represent independent risk factors for rheumatoid arthritis as well as Crohn’s disease, but not for scleroderma. (PMID:17606463)
• Variants in the IL23R gene confer a similar magnitude of risk of CD to children as for their adult counterparts. (PMID:17618837)
• Polymorphisms do not appear to play an important role in the susceptibility or severity of systemic lupus erythematosus. (PMID:17661912)
• We conclude that the IL23R gene does not seem to be associated with rheumatoid arthritis predisposition in a Spanish population. (PMID:17678723)
• IL23R gene is one of the genetic factors implicated in the genetics of IBD in the general population. (PMID:17678845)
• There was no evidence for epistasis between the IL23R gene and the Crohn’s disease susceptibility genes CARD15 and SLC22A4/5. (PMID:17786191)
• IL23R is an established gene locus for Crohn Disease. (PMID:17804789)
• Interleukin-23R Arg381Gln is associated with susceptibility to Crohn’s disease but not with phenotype in an Italian population. (PMID:17854611)
• IL25R R391Q is strongly associated with Crohn’s disease in New Zealand Caucasians with inflammatory bowel disease. (PMID:17894849)
• four variants (rs11209026, rs7517847, rs1343151, rs10889677) of IL-23R and the A1188C polymorphism (rs3212227) of IL-12B are unlikely to be major contributors to the pathogenesis of myocardial infarction (PMID:17901940)
• Single nucleotide polymorphism in IL23R gene is associated with ankylosing spondylitis (PMID:17952073)
• IL23R genotypes influence IL-22 serum expression, linking genetic Crohn disease susceptibility to Th17 cell function for the first time (PMID:18022867)
• The IL-23 receptor gene coding variant allele R381Q appears to decrease susceptibility to Crohn Disease in an Israeli Jewish population. We found a trend toward earlier age of onset, but no interactions with CARD15 or modifying effect on disease location. (PMID:18030204)
• polymorphism associated with early onset psoriasis (PMID:18034172)
• confirmed the association of IL23R and ATG16L1 with CD susceptibility and also the association of IL23R with UC. We found IL23R and ATG16L1 were not associated with celiac disease susceptibility. (PMID:18047540)
• Variants in the IL-23R gene are strongly associated with Graves’ ophthalmopathy (GO). These variants may predispose to GO by changing the expression and/or function of IL-23R, thereby promoting a proinflammatory signaling cascade. (PMID:18073300)
• no strong evidence was present in this study to support a role for the IL12B/IL23R psoriasis-associated SNPs in multiple sclerosis susceptibility; the potential role of other, unlinked SNPs in these genes with a very modest influence cannot be excluded (PMID:18082575)
• No differences were found among 32 SNPS tagging all parts of the gene or haplotypes in patients and controls. It is unlikely that the IL23R gene confers any significant risk for MS. (PMID:18164077)
• These results together with very recent findings strongly suggest that the IL23R gene seems to be one of the genetic markers involved in AS susceptibility and support the hypothesis of a common genetic background for AS and IBD (PMID:18199597)
• CARD15 and IL23R confer susceptibility to CD in the Brazilian population. However, the presence of these variants did not influence disease phenotype. (PMID:18200510)
• Among recipients of hematopoietic cells from HLA-identical donors, the IL-23R (Arg381Gln) gene variant on the donor side has a protective effect on the occurrence of acute GVHD in recipients after transplantation. (PMID:18209723)
• Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. (PMID:18219280)
• Our findings also suggest that polymorphisms at IL23R and TNFRSF1A, and possibly HLA and TLR4, loci may account for phenotypic variation in IBD. (PMID:18338763)
• It appears that IL23R is a susceptibility locus for celiac disease and multiple sclerosis. (PMID:18368064)
• case control analysis demonstrates a disease association with the IL-23R (interleukin 23 receptor ) locus and implicates the same polymorphisms associated with Inflammatory Bowel Disease and psoriasis (PMID:18383363)
• Single nucleotide polymorphism in IL23R is associated with inflammatory bowel disease. (PMID:18383521)
• IL23R haplotype variations are associated with Crohn’s disease (PMID:18470928)
• IL23R gene is associated with Crohn disease susceptibility in Hungarian patients. (PMID:18499543)
• interleukin23R (IL23R)variants are not associated with rheumatoid arthritis (PMID:18512797)
• ATG16L1, IBD5, and IL23R SNPs were significantly associated with Crohn’s Disease (PMID:18521914)
• the 1142G/A variant of the IL23R gene was found to be a risk variant in Barrett’s esophagus patients (PMID:18560602)
• An intronic insertion was discovered between exons 9 and 10 of IL23R and termed exon 9a. This insertion has homology to the L1 retrotransposon protein and causes early translation termination. (PMID:18615094)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	ghrb	ENSDARG00000007671
danio_rerio	il11ra	ENSDARG00000026736
danio_rerio	lifrb	ENSDARG00000039863
danio_rerio	ghra	ENSDARG00000054771
danio_rerio	lifra	ENSDARG00000098857
danio_rerio	il6r	ENSDARG00000104474
mus_musculus	Il23r	ENSMUSG00000049093
rattus_norvegicus	Il23r	ENSRNOG00000007544

Paralogs (23): CRLF1 (ENSG00000006016), IL12RB2 (ENSG00000081985), IL5RA (ENSG00000091181), IL12RB1 (ENSG00000096996), IL27RA (ENSG00000104998), EBI3 (ENSG00000105246), GHR (ENSG00000112964), PRLR (ENSG00000113494), LIFR (ENSG00000113594), LEPR (ENSG00000116678), CSF3R (ENSG00000119535), CNTFR (ENSG00000122756), IL13RA2 (ENSG00000123496), IL13RA1 (ENSG00000131724), IL6ST (ENSG00000134352), IL11RA (ENSG00000137070), OSMR (ENSG00000145623), IL2RG (ENSG00000147168), IL6R (ENSG00000160712), IL31RA (ENSG00000164509), IL3RA (ENSG00000185291), CSF2RA (ENSG00000198223), CRLF2 (ENSG00000205755)

Protein

Protein identifiers

Interleukin-23 receptor — Q5VWK5 (reviewed: Q5VWK5)

All UniProt accessions (19): A0A0D9SFJ7, A0A1B0GV19, A0A8V8TKQ4, A0A8V8TKQ8, A0A8V8TKR3, A0A8V8TKS2, A0A8V8TKS9, A0A8V8TKV7, A0A8V8TL38, Q5VWK5, A0A8V8TL42, A0A8V8TL70, A0A8V8TL76, A0A8V8TM17, A0A8V8TM22, A0A8V8TM90, A0A8V8TM95, A0A8V8TMD5, A0A8V8TME0

UniProt curated annotations — full annotation on UniProt →

Function. Associates with IL12RB1 to form the interleukin-23 receptor. Binds IL23 and mediates T-cells, NK cells and possibly certain macrophage/myeloid cells stimulation probably through activation of the Jak-Stat signaling cascade. IL23 functions in innate and adaptive immunity and may participate in acute response to infection in peripheral tissues. IL23 may be responsible for autoimmune inflammatory diseases and be important for tumorigenesis.

Subunit / interactions. Heterodimer with IL12RB1. In presence of IL23, the heterodimer forms the IL23 receptor. Interacts with JAK2 and in presence of IL23 with STAT3.

Subcellular location. Cell membrane.

Tissue specificity. Expressed by monocytes, Th1, Th0, NK and dendritic cells. Isoform 1 is specifically expressed in NK cells.

Post-translational modifications. Phosphorylated in response to IL23.

Disease relevance. Inflammatory bowel disease 17 (IBD17) [MIM:612261] A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Disease susceptibility is associated with variants affecting the gene represented in this entry.

Miscellaneous. Produced by translation in an alternate frame of the cDNA encoding isoform 4. Produced by translation in an alternate frame of the cDNA encoding isoform 5. Produced by translation in an alternate frame of the cDNA encoding isoform 2. Produced by translation in an alternate frame of the cDNA encoding isoform 3.

Similarity. Belongs to the type I cytokine receptor family. Type 2 subfamily.

Isoforms (7)

UniProt ID	Names	Canonical?
Q5VWK5-1	1, IL-23R1	yes
Q5VWK5-2	2, IL-23R2-F2
Q5VWK5-3	3, IL-23R3-F1
Q5VWK5-4	4, IL-23R2-F1
Q5VWK5-5	5, IL-23R3-F3
Q5VWK5-6	6, IL-23R6
Q5VWK5-7	7, IL-23R5

RefSeq proteins (1): NP_653302* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003961	FN3_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR052672	Type1_Cytokine_Rcpt_Type2	Family

UniProt features (63 total): strand 24, splice variant 10, glycosylation site 8, sequence conflict 6, sequence variant 4, topological domain 2, helix 2, turn 2, domain 2, signal peptide 1, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
5MZV	X-RAY DIFFRACTION	2.8
9MFG	X-RAY DIFFRACTION	2.85
6WDQ	X-RAY DIFFRACTION	3.4
8OE4	ELECTRON MICROSCOPY	3.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5VWK5-F1	68.76	0.43

Antibody-complex structures (SAbDab): 2 — 5MZV, 9MFG

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (8): 141, 180, 232, 262, 273, 29, 47, 81

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-6785807	Interleukin-4 and Interleukin-13 signaling
R-HSA-9020933	Interleukin-23 signaling

MSigDB gene sets: 442 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_POSITIVE_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_REGULATION_OF_OSTEOCLAST_DIFFERENTIATION, GOBP_REGULATION_OF_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_POSITIVE_REGULATION_OF_HEMOPOIESIS, GOBP_POSITIVE_REGULATION_OF_CELL_FATE_COMMITMENT, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOBP_RESPONSE_TO_PEPTIDE, GOBP_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE, GOBP_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE, GOBP_ALPHA_BETA_T_CELL_DIFFERENTIATION

GO Biological Process (28): positive regulation of T cell mediated cytotoxicity (GO:0001916), positive regulation of defense response to virus by host (GO:0002230), positive regulation of T-helper 1 type immune response (GO:0002827), inflammatory response (GO:0006954), cell surface receptor signaling pathway via JAK-STAT (GO:0007259), positive regulation of cell population proliferation (GO:0008284), cytokine-mediated signaling pathway (GO:0019221), response to lipopolysaccharide (GO:0032496), negative regulation of interleukin-10 production (GO:0032693), positive regulation of granulocyte macrophage colony-stimulating factor production (GO:0032725), positive regulation of type II interferon production (GO:0032729), positive regulation of interleukin-12 production (GO:0032735), positive regulation of interleukin-17 production (GO:0032740), positive regulation of natural killer cell proliferation (GO:0032819), response to type II interferon (GO:0034341), interleukin-23-mediated signaling pathway (GO:0038155), positive regulation of T cell proliferation (GO:0042102), positive regulation of activated T cell proliferation (GO:0042104), positive regulation of memory T cell differentiation (GO:0043382), positive regulation of osteoclast differentiation (GO:0045672), defense response to Gram-negative bacterium (GO:0050829), positive regulation of NK T cell activation (GO:0051135), cell surface receptor signaling pathway via STAT (GO:0097696), positive regulation of T-helper 17 type immune response (GO:2000318), positive regulation of T-helper 17 cell lineage commitment (GO:2000330), immune system process (GO:0002376), prolactin signaling pathway (GO:0038161), innate immune response (GO:0045087)

GO Molecular Function (8): cytokine receptor activity (GO:0004896), prolactin receptor activity (GO:0004925), peptide hormone binding (GO:0017046), cytokine binding (GO:0019955), interleukin-12 receptor binding (GO:0005143), protein binding (GO:0005515), interleukin-23 binding (GO:0042019), interleukin-23 receptor activity (GO:0042020)

GO Cellular Component (6): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), signaling receptor complex (GO:0043235), interleukin-23 receptor complex (GO:0072536), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Signaling by Interleukins	1
Interleukin-12 family signaling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of cytokine production	4
positive regulation of lymphocyte proliferation	2
cytokine-mediated signaling pathway	2
cytokine binding	2
cytokine receptor activity	2
cellular anatomical structure	2
positive regulation of leukocyte mediated cytotoxicity	1
T cell mediated cytotoxicity	1
regulation of T cell mediated cytotoxicity	1
positive regulation of T cell mediated immunity	1
regulation of defense response to virus by host	1
positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	1
regulation of T-helper 1 type immune response	1
T-helper 1 type immune response	1
defense response	1
cell surface receptor signaling pathway via STAT	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
negative regulation of cytokine production	1
interleukin-10 production	1
regulation of interleukin-10 production	1
granulocyte macrophage colony-stimulating factor production	1
regulation of granulocyte macrophage colony-stimulating factor production	1
positive regulation of protein metabolic process	1
type II interferon production	1
regulation of type II interferon production	1
interleukin-12 production	1
regulation of interleukin-12 production	1
interleukin-17 production	1
regulation of interleukin-17 production	1
natural killer cell proliferation	1
positive regulation of natural killer cell activation	1
regulation of natural killer cell proliferation	1
response to cytokine	1

Protein interactions and networks

STRING

1555 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL23R	IL12RB1	P42701	998
IL23R	JAK2	O60674	953
IL23R	IL17A	Q16552	922
IL23R	IL10	P22301	914
IL23R	IL17F	Q96PD4	914
IL23R	IL23A	Q9NPF7	905
IL23R	NOD2	Q9HC29	905
IL23R	TYK2	P29597	895
IL23R	IFNG	P01579	879
IL23R	RORC	P51449	859
IL23R	IL22	Q9GZX6	848
IL23R	TNF	P01375	825
IL23R	STAT4	Q14765	822
IL23R	TBX21	Q9UL17	816
IL23R	CD4	P01730	804

IntAct

10 interactions, top by confidence:

A	B	Type	Score
IL23A	IL12B	psi-mi:“MI:0914”(association)	0.810
IL23R	C1D	psi-mi:“MI:0915”(physical association)	0.560
IL23R	IL23A	psi-mi:“MI:0407”(direct interaction)	0.520
Jak2	IL23R	psi-mi:“MI:0915”(physical association)	0.500
IL12RB1	IL23R	psi-mi:“MI:0915”(physical association)	0.400
IL23R	Stat3	psi-mi:“MI:0914”(association)	0.350
IL23R	ZFTRAF1	psi-mi:“MI:0914”(association)	0.350

BioGRID (12): IL23R (Two-hybrid), IL23R (Affinity Capture-MS), IL23R (Affinity Capture-Western), IL23R (Reconstituted Complex), IL23R (Positive Genetic), CYHR1 (Affinity Capture-MS), ACTB (Affinity Capture-MS), ACTC1 (Affinity Capture-MS), PRKCA (Affinity Capture-MS), PDF (Affinity Capture-MS), IL23R (Affinity Capture-MS), LIG4 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0MSX9, A5HJM1, C8AW46, C8AW47, K9JA28, O02671, O35664, O46561, O70458, P05710, P14787, P15260, P15261, P16297, P16471, P16871, P16872, P16882, P26896, P48356, P48357, P48551, P97378, Q08501, Q13651, Q28172, Q28235, Q38IC7, Q38J85, Q3SYS8, Q4W815, Q5VWK5, Q61727, Q62959, Q63257, Q65Z14, Q6JTA8, Q6PHB0, Q80VH0, Q80XZ4

Diamond homologs: Q5VWK5, Q8K4B4

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
IL23R	“form complex”	“Interleukin-23 receptor-ligand complex”	binding
IL23A	up-regulates	IL23R	binding
IL23R	up-regulates	JAK2	binding
IL23R	up-regulates	STAT4
IL23R	up-regulates	TYK2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

445 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	252
Likely benign	157
Benign	21

Top pathogenic / likely-pathogenic (0)

SpliceAI

3130 predictions. Top by Δscore:

Variant	Effect	Δscore
1:67168088:CCAG:C	acceptor_gain	1.0000
1:67168089:CAG:C	acceptor_gain	1.0000
1:67168090:A:AG	acceptor_gain	1.0000
1:67168090:AGA:A	acceptor_gain	1.0000
1:67168090:AGAG:A	acceptor_gain	1.0000
1:67168091:G:GG	acceptor_gain	1.0000
1:67168091:GA:G	acceptor_gain	1.0000
1:67168091:GAG:G	acceptor_gain	1.0000
1:67168091:GAGG:G	acceptor_gain	1.0000
1:67169336:TTCTA:T	acceptor_loss	1.0000
1:67169337:TCTA:T	acceptor_loss	1.0000
1:67169338:CTAG:C	acceptor_loss	1.0000
1:67169339:TAG:T	acceptor_loss	1.0000
1:67169341:G:A	acceptor_loss	1.0000
1:67182956:AGAGG:A	donor_loss	1.0000
1:67182957:GAG:G	donor_gain	1.0000
1:67182957:GAGG:G	donor_loss	1.0000
1:67182958:AGG:A	donor_loss	1.0000
1:67182959:GGTA:G	donor_loss	1.0000
1:67182960:G:A	donor_loss	1.0000
1:67182961:T:A	donor_loss	1.0000
1:67200735:A:G	acceptor_gain	1.0000
1:67227130:C:CT	acceptor_gain	1.0000
1:67227130:C:T	acceptor_gain	1.0000
1:67168087:TCCAG:T	acceptor_gain	0.9900
1:67168088:CCA:C	acceptor_loss	0.9900
1:67168090:A:AC	acceptor_loss	0.9900
1:67168090:AGAGG:A	acceptor_gain	0.9900
1:67168091:GAGGG:G	acceptor_gain	0.9900
1:67168188:G:GT	donor_gain	0.9900

AlphaMissense

4182 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:67182865:T:C	C133R	0.990
1:67182904:T:A	W146R	0.990
1:67182904:T:C	W146R	0.990
1:67182898:T:C	C144R	0.988
1:67200832:T:A	V196D	0.988
1:67200845:C:A	N200K	0.985
1:67200845:C:G	N200K	0.985
1:67182906:G:C	W146C	0.984
1:67182906:G:T	W146C	0.984
1:67182898:T:A	C144S	0.983
1:67182899:G:C	C144S	0.983
1:67169427:C:G	C52W	0.981
1:67200826:T:A	V194D	0.981
1:67207050:T:A	W265R	0.981
1:67207050:T:C	W265R	0.981
1:67182900:C:G	C144W	0.980
1:67169425:T:C	C52R	0.979
1:67169572:T:C	C101R	0.979
1:67219650:T:C	F292S	0.979
1:67169574:C:G	C101W	0.978
1:67182867:T:G	C133W	0.978
1:67219696:G:C	W307C	0.977
1:67219696:G:T	W307C	0.977
1:67219649:T:C	F292L	0.976
1:67219651:T:A	F292L	0.976
1:67219651:T:G	F292L	0.976
1:67219694:T:A	W307R	0.976
1:67219694:T:C	W307R	0.976
1:67182866:G:A	C133Y	0.975
1:67206981:T:A	W242R	0.975

dbSNP variants (sampled 300 via entrez): RS10000172 (1:67179569 G>A,T), RS1000020635 (1:67250025 A>C), RS1000030177 (1:67214489 T>A), RS1000103901 (1:67173968 A>C), RS1000110783 (1:67200143 C>T), RS1000121840 (1:67246822 T>C), RS1000127746 (1:67191818 A>G), RS1000216813 (1:67150997 A>C), RS1000257804 (1:67222583 C>A,T), RS1000260473 (1:67239857 C>A,G), RS1000261501 (1:67161923 G>C), RS1000313132 (1:67266324 C>G,T), RS1000363927 (1:67167534 T>A,C), RS1000396487 (1:67167730 A>C,G), RS1000396702 (1:67185556 G>A,C)

Disease associations

OMIM: gene MIM:607562 | disease phenotypes: MIM:605606, MIM:612261

GenCC curated gene-disease

Disease	Classification	Inheritance
inherited susceptibility to mycobacterial diseases	Strong	Autosomal recessive
immunodeficiency disease	Strong	Autosomal recessive

Mondo (4): psoriasis 7, susceptibility to (MONDO:0011573), inflammatory bowel disease 17 (MONDO:0012840), inherited susceptibility to mycobacterial diseases (MONDO:0019146), immunodeficiency disease (MONDO:0021094)

Orphanet (0):

HPO phenotypes

85 total (30 of 85 shown, HPO-id order):

HPO	Term
HP:0000031	Epididymitis
HP:0000083	Renal insufficiency
HP:0000099	Glomerulonephritis
HP:0000155	Oral ulcer
HP:0000488	Retinopathy
HP:0000518	Cataract
HP:0000613	Photophobia
HP:0000618	Blindness
HP:0000708	Atypical behavior
HP:0000737	Irritability
HP:0001061	Acne
HP:0001097	Keratoconjunctivitis sicca
HP:0001250	Seizure
HP:0001251	Ataxia
HP:0001269	Hemiparesis
HP:0001287	Meningitis
HP:0001288	Gait disturbance
HP:0001289	Confusion
HP:0001347	Hyperreflexia
HP:0001369	Arthritis
HP:0001482	Subcutaneous nodule
HP:0001637	Abnormal myocardium morphology
HP:0001653	Mitral regurgitation
HP:0001658	Myocardial infarction
HP:0001659	Aortic regurgitation
HP:0001701	Pericarditis
HP:0001733	Pancreatitis
HP:0001744	Splenomegaly
HP:0001824	Weight loss
HP:0001945	Fever

GWAS associations

61 associations (top):

Study	Trait	p-value
GCST000014_1	Crohn’s disease	2.000000e-18
GCST000023_3	Crohn’s disease	3.000000e-12
GCST000042_13	Crohn’s disease	6.000000e-12
GCST000071_1	Crohn’s disease	1.000000e-08
GCST000071_2	Crohn’s disease	2.000000e-07
GCST000207_27	Crohn’s disease	7.000000e-63
GCST000225_6	Inflammatory bowel disease	7.000000e-11
GCST000311_3	Ulcerative colitis	1.000000e-08
GCST000311_8	Ulcerative colitis	1.000000e-08
GCST000322_3	Psoriasis	3.000000e-08
GCST000527_8	Ulcerative colitis	3.000000e-10
GCST000563_1	Ankylosing spondylitis	9.000000e-14
GCST000624_14	Ulcerative colitis	1.000000e-13
GCST000705_4	Crohn’s disease	1.000000e-06
GCST000726_1	Behcet’s disease	7.000000e-09
GCST000728_1	Behcet’s disease	2.000000e-11
GCST000833_15	Psoriasis	7.000000e-07
GCST000879_28	Crohn’s disease	1.000000e-64
GCST000964_11	Ulcerative colitis	5.000000e-28
GCST001149_1	Ankylosing spondylitis	2.000000e-17
GCST001292_4	Leprosy	3.000000e-11
GCST001396_1	Crohn’s disease	4.000000e-21
GCST001438_1	Crohn’s disease	1.000000e-18
GCST001652_5	Crohn’s disease	4.000000e-14
GCST001725_29	Inflammatory bowel disease	8.000000e-161
GCST002094_2	Crohn’s disease	2.000000e-10
GCST002446_2	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid)	4.000000e-06
GCST002562_1	Vogt-Koyanagi-Harada syndrome	3.000000e-21
GCST002740_62	Inflammatory skin disease	2.000000e-10
GCST002772_1	Leprosy	4.000000e-33

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0005680	omega-6 polyunsaturated fatty acid measurement
EFO:1001494	psoriasis vulgaris
EFO:0007874	gut microbiome measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C567378	Inflammatory Bowel Disease 17 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4296013 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

2 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs11209026	Toxicity	3	Tumor necrosis factor alpha (TNF-alpha) inhibitors	Psoriasis
rs7518660	Toxicity	3	celecoxib	Colorectal Neoplasms

PharmGKB variants

5 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs7518660	IL23R	3	2.50	1	celecoxib
rs11805303	IL23R		0.00	0
rs11209026	IL23R	3	3.00	1	Tumor necrosis factor alpha (TNF-alpha) inhibitors
rs6683455	IL23R		0.00	0
rs10489629	IL23R		0.00	0

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — IL-12 receptor family

ChEMBL bioactivities

577 potent at pChembl≥5 of 595 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.80	IC50	1.6	nM	CHEMBL6160466
8.74	Kd	1.81	nM	CHEMBL4206167
8.70	IC50	2	nM	CHEMBL4548141
8.62	Kd	2.4	nM	CHEMBL4206167
8.62	Kd	2.42	nM	CHEMBL4206167
8.57	IC50	2.7	nM	CHEMBL4206167
8.52	IC50	3	nM	CHEMBL4472666
8.49	IC50	3.2	nM	CHEMBL6152345
8.32	IC50	4.8	nM	CHEMBL6167841
8.30	IC50	5	nM	CHEMBL4563692
8.29	IC50	5.1	nM	CHEMBL4206167
8.22	IC50	6	nM	CHEMBL4564895
8.21	IC50	6.2	nM	CHEMBL6172818
8.15	IC50	7	nM	CHEMBL4459734
8.10	IC50	8	nM	CHEMBL4458363
8.00	IC50	10	nM	CHEMBL4439312
8.00	IC50	10	nM	CHEMBL4452929
8.00	IC50	10	nM	CHEMBL4458963
8.00	IC50	10	nM	CHEMBL4587092
8.00	IC50	10	nM	CHEMBL4452494
8.00	IC50	10	nM	CHEMBL4450713
8.00	IC50	10	nM	CHEMBL4463499
8.00	IC50	10	nM	CHEMBL4462027
8.00	IC50	10	nM	CHEMBL4548723
8.00	IC50	10	nM	CHEMBL4534168
8.00	IC50	10	nM	CHEMBL4553942
8.00	IC50	10	nM	CHEMBL4522013
8.00	IC50	10	nM	CHEMBL4518617
8.00	IC50	10	nM	CHEMBL4476293
8.00	IC50	10	nM	CHEMBL4466143
8.00	IC50	10	nM	CHEMBL4462751
8.00	IC50	10	nM	CHEMBL4452274
8.00	IC50	10	nM	CHEMBL4537284
8.00	IC50	10	nM	CHEMBL4436299
8.00	IC50	10	nM	CHEMBL4550183
8.00	IC50	10	nM	CHEMBL4465744
8.00	IC50	10	nM	CHEMBL4457047
8.00	IC50	10	nM	CHEMBL4437079
8.00	IC50	10	nM	CHEMBL4556182
8.00	IC50	10	nM	CHEMBL4550133
8.00	IC50	10	nM	CHEMBL4206167
8.00	IC50	10	nM	CHEMBL4580023
8.00	IC50	10	nM	CHEMBL4465938
8.00	IC50	10	nM	CHEMBL4461779
8.00	IC50	10	nM	CHEMBL4546880
8.00	IC50	10	nM	CHEMBL4516330
8.00	IC50	10	nM	CHEMBL4576566
8.00	IC50	10	nM	CHEMBL4577277
8.00	IC50	10	nM	CHEMBL4522401
8.00	IC50	10	nM	CHEMBL4437837

PubChem BioAssay actives

3 with measured affinity, of 5 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(4S)-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(3R,6S,9S,12S,15S,18S)-18-acetamido-6,15-bis(3-amino-3-oxopropyl)-12-[(1R)-1-hydroxyethyl]-9-(1H-indol-3-ylmethyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carbonyl]amino]-3-[4-(2-aminoethoxy)phenyl]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-amino-2-methylhexanoyl]amino]-5-[[(2S)-4-amino-1-[(2-amino-2-oxoethyl)amino]-1,4-dioxobutan-2-yl]amino]-5-oxopentanoic acid	1387610: Binding affinity to recombinant human flag/His-tagged IL-23R (1 to 353 residues) expressed in HEK293F cells measured over 90 secs by surface plasmon resonance assay	kd	0.0018	uM

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
2-(1’H-indole-3’-carbonyl)thiazole-4-carboxylic acid methyl ester	increases expression, decreases expression, affects expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, increases methylation	2
CBP30 compound	decreases expression	1
bisphenol F	decreases methylation	1
fluorene-9-bisphenol	increases expression	1
bisphenol A	decreases methylation	1
sodium arsenite	increases expression	1
N-acetyl-4-benzoquinoneimine	affects response to substance	1
6-formylindolo(3,2-b)carbazole	affects expression	1
(+)-JQ1 compound	decreases expression	1
Glyphosate	decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Methotrexate	decreases expression	1
Phthalic Acids	decreases methylation	1
Tretinoin	decreases expression	1
Aflatoxin B1	increases methylation	1
Zinc Sulfate	decreases expression	1

ChEMBL screening assays

13 unique, capped per target: 13 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4202300	Binding	Binding affinity to recombinant human flag/His-tagged IL-23R (1 to 353 residues) expressed in HEK293F cells measured over 90 secs by surface plasmon resonance assay	Deciphering Binding Interactions of IL-23R with HDX-MS: Mapping Protein and Macrocyclic Dodecapeptide Ligands. — ACS Med Chem Lett

Cellosaurus cell lines

6 cell lines: 4 cancer cell line, 2 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A8CH	HEK-Blue IL-23	Transformed cell line	Female
CVCL_B8ID	Abcam HCT 116 IL23R KO	Cancer cell line	Male
CVCL_B9KM	Abcam A-549 IL23R KO	Cancer cell line	Male
CVCL_D2FU	Abcam MCF-7 IL23R KO	Cancer cell line	Female
CVCL_E4JC	Genomeditech HEK-293 H_IL23 Reporter	Transformed cell line	Female
CVCL_E7RR	iLite IL-23 Assay Ready Cells	Cancer cell line	Female

Clinical trials (associated diseases)

247 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00001542	PHASE4	COMPLETED	Fluconazole Prophylaxis of Thrush in AIDS
NCT00144157	PHASE4	COMPLETED	Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV
NCT00162643	PHASE4	UNKNOWN	PI Vs. NNRTI Based Therapy for HIV Advanced Disease
NCT00273988	PHASE4	COMPLETED	Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
NCT00981318	PHASE4	TERMINATED	Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
NCT01086878	PHASE4	COMPLETED	Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
NCT01090102	PHASE4	COMPLETED	Mesalamine to Reduce T Cell Activation in HIV Infection
NCT01147042	PHASE4	TERMINATED	Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
NCT01230580	PHASE4	UNKNOWN	Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)
NCT01465958	PHASE4	COMPLETED	Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
NCT02274662	PHASE4	COMPLETED	Expanded Access Protocol Thymus Transplantation
NCT02348177	PHASE4	COMPLETED	Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
NCT02396979	PHASE4	COMPLETED	Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia
NCT02490956	PHASE4	UNKNOWN	Diagnostic Immunization With Rabies Vaccine in Patients With PID
NCT02503293	PHASE4	COMPLETED	A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
NCT02881437	PHASE4	COMPLETED	IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
NCT03033745	PHASE4	COMPLETED	Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
NCT03677557	PHASE4	UNKNOWN	Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
NCT04192487	PHASE4	COMPLETED	Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea
NCT04566692	PHASE4	COMPLETED	A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
NCT05493969	PHASE4	NOT_YET_RECRUITING	Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity
NCT06576024	PHASE4	COMPLETED	Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People
NCT06634641	PHASE4	RECRUITING	Clozapine-related Immunodeficiency in Parkinsons Disease
NCT07076446	PHASE4	ACTIVE_NOT_RECRUITING	An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
NCT00000118	PHASE3	COMPLETED	Ganciclovir Implant Study for Cytomegalovirus Retinitis
NCT00000134	PHASE3	COMPLETED	Studies of the Ocular Complications of AIDS (SOCA)–Cytomegalovirus Retinitis Retreatment Trial (CRRT)
NCT00000590	PHASE3	COMPLETED	Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
NCT00001267	PHASE3	COMPLETED	A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2’,3’-Dideoxyinosine
NCT00001646	PHASE3	COMPLETED	Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
NCT00144183	PHASE3	COMPLETED	A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)
NCT00243568	PHASE3	WITHDRAWN	Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
NCT00278954	PHASE3	COMPLETED	Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
NCT00474370	PHASE3	COMPLETED	Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
NCT00478231	PHASE3	COMPLETED	Multicenter, Safety Study Of Maraviroc
NCT00523211	PHASE3	COMPLETED	Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
NCT00698334	PHASE3	COMPLETED	Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis
NCT00966160	PHASE3	COMPLETED	CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
NCT01363011	PHASE3	COMPLETED	Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
NCT01440569	PHASE3	COMPLETED	Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01475838	PHASE3	COMPLETED	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients